Suraksha Diagnostics has inaugurated a state-of-the-art genomics laboratory in Kolkata, setting a new benchmark for genetic diagnostics in Eastern India. The lab was launched in the presence of renowned rheumatologist Prof. Sukumar Mukherjee, who also serves as a mentor to Suraksha Diagnostics.
Strengthening Bengal’s Healthcare Infrastructure
Located in West Bengal, the new facility reflects the region’s ongoing transformation in medical services and education. Suraksha Diagnostics stated that the lab caters to the rising demand for accessible and accurate genomic testing, supporting the broader shift toward preventive and risk-based healthcare.
Strategic Investments to Build a Genomic Powerhouse
Recognizing the growing global demand for genetic testing, Suraksha Diagnostics has invested ₹22 crore into setting up the facility. Furthermore, the organization plans to invest an additional ₹46 crore over the next two years to scale capabilities, with the vision of making it one of Asia’s most advanced genomics laboratories.
According to market estimates, the global genetic testing industry is valued at USD 38.77 billion in 2024 and is projected to reach USD 186.64 billion by 2035, growing at a CAGR of 22.5%.
Equipped with Cutting-Edge Genomic Technologies
The lab boasts a full suite of genomic technologies including:
- Cytogenetics
- Microarray analysis
- Sanger sequencing
- Multiple next-generation sequencing (NGS) platforms
These tools support a wide spectrum of genetic diagnostics, enabling predictive, preventive, and personalised healthcare.
Comprehensive Services in Prenatal and Oncology Genetics
As reported by Express Healthcare, the genomics lab offers prenatal screening for chromosomal abnormalities like Down syndrome, Edwards syndrome, and Patau syndrome, supported by genetic counselling to empower expecting families with informed decision-making.
In oncology, the lab provides hereditary cancer panels that detect genetic predispositions to conditions such as breast, ovarian, and colorectal cancers. It also conducts germline and somatic mutation profiling, delivering targeted oncology panels through NGS to facilitate precision-based treatment.
Robust Diagnostic Workflow for Accurate Insights
Suraksha’s genomic diagnostic process begins with karyotyping to evaluate chromosomal structures, followed by chromosomal microarray to identify smaller anomalies. The lab also uses FISH (Fluorescence in situ Hybridisation) for detecting specific genetic conditions. For individual gene analysis, Sanger sequencing is used, while NGS scans large volumes of genomic data for deeper insights.
Leadership Speaks on the Genomic Revolution
Dr. Somnath Chatterjee, Chairman and Joint Managing Director of Suraksha Diagnostics, emphasized the transformative potential of genomics:
“A huge transformation is sweeping across medicine today. At the heart of this revolution lies Genomics—unlocking the secrets of the human genome to enable early diagnosis, predictive analytics, and personalised treatment. From fetal medicine to oncology and rare diseases, genomic science is rewriting the future of healthcare. Suraksha Diagnostics is proud to lead this change.”
Echoing this vision, Ritu Mittal, CEO and Managing Director at Suraksha Diagnostics, added:
“We offer end-to-end solutions in prenatal genetics, providing high-quality, comprehensive testing. Our goal is to become the first-choice genomics provider for clinicians and families seeking excellence in fetal, reproductive, pediatric, and cancer genetics—without needing to send samples outside the region or compromising on quality.”
Pioneering Genomics for a Healthier Tomorrow
With this new genomics lab, Suraksha Diagnostics takes a major leap toward precision medicine. The facility is poised to drive advancements in diagnosis, risk prediction, and personalised care, cementing its role as a regional leader in genetic diagnostics.